Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.24%
1,103.05
+2.67
+0.24%
—1,100.381,096.191,112.971,094.08——
SIXC
Communications
SIXC
Communications
SIXC
+0.19%
622.42
+1.21
+0.19%
—621.21621.21624.47618.56——
SIXE
Energy
SIXE
Energy
SIXE
-2.87%
1,157.44
-34.22
-2.87%
—1,191.661,158.281,160.761,124.17——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.82%
1,750.30
+31.25
+1.82%
—1,719.051,729.911,766.941,729.91——
SIXM
Financials
SIXM
Financials
SIXM
+0.75%
646.61
+4.84
+0.75%
—641.77643.39653.21643.39——
SIXR
Staples
SIXR
Staples
SIXR
+1.26%
833.78
+10.40
+1.26%
—823.38822.99834.38820.61——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.54%
218.49
+3.31
+1.54%
—215.18215.18218.76215.18——
SIXT
Technology
SIXT
Technology
SIXT
+1.50%
3,109.02
+45.83
+1.50%
—3,063.193,096.933,118.043,093.29——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.42%
935.18
-3.92
-0.42%
—939.10937.35937.41924.95——
SIXV
Health care
SIXV
Health care
SIXV
+1.45%
1,503.60
+21.56
+1.45%
—1,482.041,485.591,506.801,485.59——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+2.36%
2,435.30
+56.09
+2.36%
—2,379.212,409.512,463.802,409.51——
CSL Ltd
A$137.13
-0.31%
(-0.42) 1D
Apr 17, 4:11:51 PM GMT+10  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for CSL...
Open
A$137.55
High
A$138.25
Low
A$135.95
Mkt. cap
66.55B
Avg. vol.
1.27M
Volume
1.54M
Dividend
2.17%
Quarterly dividend
A$0.75
Ex dividend date
Sep 9, 2025
P/E ratio
34.03
52-wk high
A$275.79
52-wk low
A$133.35
EPS
A$4.03
Shares outstanding
485.32M
No. of employees
30K
News stories
From sources across the web
Profile
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994. Wikipedia
About CSL Ltd
CEOPaul McKenzie
Employees29.9K
Founded1916
HeadquartersMelbourne, Victoria, Australia
SectorBiotechnology
Websitecsl.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
3.54B
3.54B
4.17B
4.17B
Cost of goods sold
1.77B
1.77B
1.94B
1.94B
Cost of revenue
1.77B
1.77B
1.94B
1.94B
Research and development expenses
356.50M
356.50M
300.00M
300.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
718.00M
718.00M
612.50M
612.50M
Operating expense
1.07B
1.07B
912.50M
912.50M
Total operating expenses
2.85B
2.85B
2.85B
2.85B
Operating income
690.50M
690.50M
1.32B
1.32B
Other non operating income
-
-
-
-
EBT including unusual items
592.00M
592.00M
190.00M
190.00M
EBT excluding unusual items
596.50M
596.50M
1.22B
1.22B
Income tax expense
52.00M
52.00M
47.00M
47.00M
Effective tax rate
8.78%
8.78%
24.74%
24.74%
Other operating expenses
-
-
-
-
Net income
497.50M
497.50M
200.50M
200.50M
Net profit margin
14.06%
14.06%
4.81%
4.81%
Earnings per share
-
-
-
-
Interest and investment income
10.00M
10.00M
9.00M
9.00M
Interest expense
-104.00M
-104.00M
-106.50M
-106.50M
Net interest expenses
-94.00M
-94.00M
-97.50M
-97.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
855.00M
855.00M
1.56B
1.56B
Gain or loss from assets sale
7.00M
7.00M
22.50M
22.50M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer